18 results about "Medical therapy" patented technology

A method of conducting operations for an IPG adapted to provide electrical pulses to tissue of a patient for medical therapy is provided. The IPG provides the medical therapy according to pulse parameter data executed according to an execution path. The method can include identifying a root node repeated within the execution path of a first set of the pulse parameter data, identifying a stimulation pulse pattern repeated in the first set between occurrences of the root node, replacing the repeated pattern with (a) a single instance and a recurrence count or (b) a pointer to a reference pattern to generate a second set of the pulse parameter data, and communicating the second set between the external controller and the IPG and / or storing the second set within a memory of the IPG.

Provided herein are systems and methods for selecting a weight loss medication using a machine learning model to address obesity. A computing system may receive physiological measurements of a user. The computing system may apply the measurements to a machine learning model. The machine learning model may be trained using a plurality of examples, each example comprising sample physiological measurements of a sample user and a corresponding sample weight loss medication administered to the sample user. The computing system may generate based on applying the one or more physiological measurements to the machine learning model, a metric indicating an expected outcome associated with a weight loss medication for the user. The computing system may provide to a user device associated with the user, a message indicating the expected outcome associated with the weight loss medication. The computing system can improve efficacy of the medication in addressing the obesity.

1. Name of the product in this design: Portable micro-mesh atomizer for infants and toddlers (lion shape). 2. Purpose of this design: A micro-mesh nebulizer for use in the medical device field to treat infants and young children with respiratory diseases. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. Other situations requiring explanation: The area shown in part A of the 3D diagram 1 is a transparent design.

The present invention provides CR2 binding proteins which bind to human CR2, pharmaceutical compositions comprising said CR2 binding proteins and their use in the treatment or prevention of autoimmune and / or inflammatory conditions, infectious diseases and malignancies associated with the Epstein-Barr virus (EBV); and their use as vaccine adjuvants / antigen carriers.

The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.

To provide novel compounds for use in the treatment or prevention of cancer and other proliferative conditions. [Solution] The present invention relates to novel compounds for use in the treatment or prevention of cancer and other proliferative conditions, characterized, for example, by cells expressing cytochrome P450 1B1 (CYP1B1) and its allele variants. The present invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapies, for example, in the treatment or prevention of cancer or other proliferative conditions, as well as methods for treating cancer or other conditions in human or non-human animal patients. The present invention also provides methods for identifying novel compounds for use in the treatment or prevention of cancer and other proliferative conditions, characterized, for example, by cells expressing CYP1B1 and its allele variants. The present invention also provides methods for determining the efficacy of the compounds of the present invention in cancer treatment.

Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

The present disclosure relates to novel lamotrigine salts, co-crystals, and compositions. In some embodiments, the lamotrigine salt is a lamotrigine dicarboxylic acid salt or hydrate or solvate thereof. In some embodiments, the lamotrigine co-crystal is a co-crystal of lamotrigine and a dicarboxylic acid, or a hydrate or solvate thereof. In some embodiments, the compositions comprise lamotrigine or a salt or co-crystal thereof, or a hydrate or solvate thereof. In some embodiments, the composition is in the form of a powder. In some embodiments, the composition is in the form of a liquid. The present disclosure also relates to methods of preparation and use in medical therapy, for example, for the treatment of a subject with epilepsy or bipolar disorder.

Patients with paroxysmal or persistent atrial fibrillation whose untreated atrial fibrillation exceeds the threshold level are eligible for treatment with a drug that can control the patient's heart rhythm (e.g., budiodarone). Eligible patients are treated with the drug while their heart rate is monitored using a wearable device, and if a given drug dose is deemed ineffective, the dose is adjusted until an effective dose is determined for the patient or the patient is deemed unresponsive to the drug and is discontinued from treatment.

In some examples, an apparatus, such as a mobile phone may include a camera, a processor, and computer readable medium. The camera capture one or more images of a person. The processor may use a machine learning model to predict the body volume of the person based on the captured images. The model may be trained based at a training data set comprising at least a plurality of user images. The apparatus may transmit the predicted body volume to a medication and medical treatment management system and receive from the same an adjusted medication or medical treatment plan. The apparatus may further execute the adjusted medication or medical treatment plan. 20 26 20 48 82 23 J un 2 02 6 A B S T R A C T 2 0 2 6 2 0 4 8 8 2 2 3 J u n 2 0 2 6

The invention relates to semaglutide for use in treatment of obesity or overweight of a human subject, wherein said semaglutide is administered subcutaneously in an amount of 7.2 mg per week and is no

Embodiments are directed to an implantable medical device comprising therapeutic stimulation circuitry for controlling delivery of a medical therapy to a patient, the therapeutic stimulation circuitry having at least one lead having electrodes for delivering the medical therapy, The implantable medical device further comprises measurement circuitry for determining characteristics of the at least one lead, a processor for controlling the IMD according to executable code, and memory for storing data and executable code, wherein the executable code comprises instructions for causing the processor to receive a plurality of voltage measurements associated with the electrodes, and calculate values for an impedance model of the electrode / tissue interface.